NeuroSigma Monarch eTNS Becomes The First FDA-Cleared ADHD Device
Executive Summary
The de novo clearance is based on the results of a 62-patient phase II sham-controlled trial. Patients in the treatment group showed more improvement in attention deficit hyperactivity disorder symptoms over four weeks than patients treated with a placebo device.